Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$78.6K Sell
1,216
-466,292
-100% -$32.9M ﹤0.01% 956
2025
Q4
$31.5M Buy
467,508
+341,936
+272% +$23M 0.11% 131
2025
Q3
$9.21M Buy
+125,572
New +$8.34M 0.04% 314
2025
Q2
Sell
-6,866
Closed -$435K 1088
2025
Q1
$435K Buy
6,866
+6,659
+3,217% +$387K ﹤0.01% 676
2024
Q4
$9.9K Hold
207
﹤0.01% 953
2024
Q3
$11.8K Buy
207
+13
+7% +$745 ﹤0.01% 844
2024
Q2
$10.2K Hold
194
﹤0.01% 846
2024
Q1
$7.89K Buy
194
+36
+23% +$1.35K ﹤0.01% 909
2023
Q4
$5.84K Buy
+158
New +$5.95K ﹤0.01% 958
2022
Q4
Sell
-37,600
Closed -$1.49M 1203
2022
Q3
$1.49M Sell
37,600
-30,300
-45% -$1.34M 0.01% 674
2022
Q2
$2.99M Buy
+67,900
New +$2.94M 0.01% 566
2022
Q1
Sell
-20,646
Closed -$830K 1222
2021
Q4
$830K Sell
20,646
-29,990
-59% -$1.12M ﹤0.01% 955
2021
Q3
$2.06M Buy
50,636
+37,051
+273% +$1.55M 0.01% 722
2021
Q2
$617K Sell
13,585
-23,000
-63% -$1.02M ﹤0.01% 681
2021
Q1
$1.52M Sell
36,585
-449,109
-92% -$20.5M 0.01% 761
2020
Q4
$20.7M Buy
+485,694
New +$17.5M 0.08% 249

Other funds holding HALO

Natixis's HALO Position: Q1 2026 in Review

Natixis reduced its Halozyme (HALO) stake by 100% in Q1 2026, selling an estimated $32.9M and leaving 1,216 shares worth $78.6K. The position accounts for ﹤0.01% of the portfolio, ranked #956.

Natixis first reported a position in HALO in Q4 2020 and has held it in 16 quarters since. The position peaked at $31.5M in Q4 2025. 635 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Natixis held 1,216 shares of Halozyme worth $78.6K as of Q1 2026.
  • Natixis sold 466,292 Halozyme shares in Q1 2026, an estimated $32.9M.
  • Halozyme made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #956 holding.
  • Natixis first reported a position in Halozyme in Q4 2020 and has held it in 16 quarters since.
  • Natixis's Halozyme position peaked at $31.5M in Q4 2025.
  • 635 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.